Drug substance, drug product, advanced therapy, and vaccine manufacturers run dense software estates across MES, SCADA, LIMS, QC analytics, and DSCSA serialisation. 21 CFR Part 11, EU Annex 11, GAMP 5, and active state- actor IP-theft pressure mean every release needs evidence that holds up to inspection and to an APT.
Inspector, threat-actor, and operational pressures now share a single, continuous evidence requirement.
Electronic records and signatures across manufacturing systems demand validated, tamper-evident audit trails. Spreadsheet-driven evidence collection no longer survives an inspector who arrives expecting live, queryable attestation across the entire GxP estate.
Every change to a GxP system carries a validation cost. Continuous SBOM and signed provenance turn the validation pack into a build artefact, not a parallel manual deliverable produced weeks after the change is in production.
Pharma R&D and bioprocess know-how are persistent targets for advanced adversaries operating on multi-year horizons. The intrusion path is rarely the lab itself — it is the OEM equipment vendor, the MES, or the analytics partner.
Manufacturing execution systems and process-control networks now share routes, identities, and software supply chains with IT. A CVE in a shared library can cross the air gap before the OT team has finished reading the advisory.
Pipelines emit validation artefacts in lock-step with build artefacts. IQ / OQ / PQ evidence is produced by the same release that ships the binary, signed against the commit and the build environment that produced it.
Every MES module, every PLC firmware bundle, every analytics container ships with a CycloneDX SBOM and a signed attestation. DSCSA-impacted systems carry their evidence with them, not in a separate folder on a shared drive.
Vision-model and process-analytics pipelines emit AI-BOM, training-data lineage, and drift telemetry. When the regulator asks how the QC model decides what passes, the answer is a signed query, not a slide deck.
Contract manufacturers and contract development partners introduce shared software estates. Concentration risk surfaces at the component level so procurement and quality can see the blast radius before they sign the next master services agreement.
Pre-mapped control narratives and validation evidence in the formats your QA, RA, and FDA / EMA inspector already accept.
Validated control plane inside the plant network, dedicated inference for QC and process analytics, audit log streamed to the GxP audit system, and a signed SBOM portal exposed to inspectors on a read-only basis.
Control plane sits inside the manufacturer's validated network zone. No cross-tenant traffic, no shared key material, qualification documentation generated in-line with deployment.
Single-tenant GPU pool with SHA-pinned weights and model attestation at install. The same model that scored a release is the model whose attestation lives in the validation pack.
Every action emits a signed event to the existing audit-trail store in JSON and CycloneDX. Retention, search, and review workflows stay under the QA organisation's control.
Read-only portal exposes signed SBOMs, VEX statements, validation evidence, and DSCSA serialisation lineage to inspectors on demand — no email attachments, no copy-paste questionnaires.
Manufacturing-execution-system vendors are concentrated and deeply integrated. A compromise of the vendor's release pipeline ships malicious code or bad weights to every plant that runs that release train.
Process-control HMIs run unpatched libraries that share supply chains with IT. A reachable CVE in an HMI panel can become a production-stoppage event before the OT team has confirmed the version.
Contract manufacturers and contract developers introduce shared software estates that the brand owner does not directly control. Concentration risk lives in their build pipelines as much as in yours.
Vision and analytics models that release batches are now in the GxP boundary. Adversarial input, drift, and unreviewed retraining are quality events as much as security events, and need attestation either way.
Bioreactor, fill-finish, and analytical OEM equipment phones home for telemetry and remote service. Without component-level visibility, recipe data and process know-how leak through legitimate vendor channels.
Numbers from production deployments. Same inspector, same vendor stack, dramatically less paper.
| Metric | Before Safeguard | With Safeguard |
|---|---|---|
| 21 CFR Part 11 evidence prep | 8 weeks | 1 day |
| DSCSA serialisation audit prep | 6 weeks | 4 hours |
| CMO vendor monitoring cadence | Quarterly | Continuous |
| Tool consolidation | 8 vendors | 1 |
| AI-QC attestation per release | 3 weeks | 1 hour |
| False-positive triage burden | ~80% | ~5% |
| IP-exfiltration monitoring | Reactive | Continuous |
Talk to the team about GxP-validated CI pipelines, DSCSA serialisation evidence, AI-QC attestation, and a deployment shape that lives inside your plant network.